Bristol Myers director granted deferred share units
Bristol Myers Squibb director Michael R. McMullen received a grant of 607.428 Deferred Share Units, each valued at $57.62.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Bristol Myers Squibb director Michael R. McMullen received a grant of 607.428 Deferred Share Units, each valued at $57.62. These units represent deferred compensation that will be converted into common stock when he ceases to be a director or at a previously chosen future date.
Following this award, McMullen holds a total of 16,332.540 Deferred Share Units tied to Bristol Myers Squibb common stock, including prior deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. This filing reflects a compensation-related equity award rather than an open-market stock purchase or sale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Share Units | 607.428 | $57.62 | $35K |
Footnotes (2)
- F1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
- F2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Key Figures
Key Terms
deferred compensation financial
1987 Deferred Compensation Plan for Non-Employee Directors financial
dividends reinvested financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Bristol Myers Squibb (BMY) director Michael R. McMullen report in this Form 4?
Is Michael R. McMullen’s Form 4 transaction in BMY stock a market buy or sell?
AI-generated analysis. How Rhea-AI works. Not financial advice.